Navigation Links
TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
Date:12/19/2008

SCOTTSDALE, Ariz. Dec. 19, 2008 The Translational Genomics Research Institute (TGen), Scottsdale Healthcare and Mayo Clinic are testing a new drug that could help cancer patients by stimulating the immune system.

Clinical trials of the drug VTX-2337 are being conducted at TGen Clinical Research Services at Scottsdale Healthcare, a partnership of Phoenix-based TGen and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo Clinic in Arizona.

Dr. Ramesh Ramanathan, Medical Director of TGen Clincal Research Services at Scottsdale Healthcare, said the new drug appears promising.

"VTX-2337 is a new, novel, small molecule aimed at stimulating the immune cells in the blood, lymph nodes, and in and around the tumor. It represents an exciting new class of agents for cancer therapy with good preclinical evidence of activity,'' Dr. Ramanathan said.

The Phase I trial, a yearlong first-in-humans test, will study the drug's safety. If successful, a Phase II trial will test the drug's effectiveness on tumors.

A weakened immune system is often the result of advanced cancer. The hope is that this new drug will actually help enable the immune system to slow down the growth of tumors, and perhaps even shrink them, Dr. Ramanathan said.

VTX-2337 is the first drug of its kind developed by San Diego-based VentiRx Pharmaceuticals Inc. The biopharmaceutical company is focused on the development of new Toll-Like Receptor 8 (TLR8) agonists, which are small molecules that prompt a response in the body's immune system. The drugs are intended to treat cancer, respiratory and autoimmune diseases.

"VentiRx is very excited to be working with TGen, Scottsdale Healthcare and Mayo Clinic on this important and novel program,'' said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "Entering Phase I clinical trials represents a significant milestone for VentiRx and our TLR efforts in that we have rapidly advanced into a clinical development company with a novel molecule that may play an important role and have broad application in the treatment of cancer."

VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer. Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system.

There are two broad components of the immune system, the innate arm, and the adaptive arm. Both generally aim to eliminate viruses and bacteria.

-- The innate arm senses infectious agents as they infect the body by recognizing structures they have in common, such as lipids, proteins, sugars, and nucleic acids (DNA and RNA). This is an initial rapid response, which is not precise but potent.

-- The adaptive arm of the immune system is instructed by the innate arm to devise more specific responses to unique components of the invading pathogens. This is a more precise response and takes longer, especially when an infectious agent is encountered for the first time.

The first clinical trial at TCRS at Scottsdale Healthcare will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late-stage cancer. For more information about this clinical trial, please call Joyce Ingold, R.N., research patient care coordinator for Scottsdale Healthcare, at 480-323-1339.

The clinical trial coordinator for Mayo Clinic is Dianna Boughter, who can be reached at 480-301-9875.

"VTX-2337 is the first selective TLR8 compound to reach the clinic, and we are hopeful that modulation of the innate immune response will provide a benefit to patients in a number of oncology indications," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. In just 5 years, gene discovery to clinical trial of potential treatment
2. Mayo Clinic research on tamoxifen leads to recommendation for CYP2D6 gene test
3. New book helps medical students master clinical skills
4. Biochemistry of human physiology in health and disease is focus of updated clinical text
5. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
6. A new journal where molecular biology meets clinical research
7. Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
8. Clinical trial for new tuberculosis vaccine
9. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
10. Building bridges between the clinic and the laboratory
11. New study spotlights National Institutes of Health grant outcomes for clinical research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/16/2016)... --  IdentyTechSolutions America LLC , a leading provider ... a cutting-edge manufacturer of software and hardware security ... integrated solutions that comprise IDT biometric readers and ... IdentyTech,s customers with combined physical identification and anti-tailgating ... theft. "We are proud to use ...
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... and HOUSTON , ... ("NX Prenatal") today announced the formation of its ... leading clinicians and industry veterans who enhance the ... as it accelerates development of its novel prenatal ... provide medical, clinical and strategic guidance for the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
(Date:1/19/2017)... ... 2017 , ... The American Medical Informatics Association (AMIA) today ... Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should be ... recommended that NIH earmark funding for researchers to produce and execute data sharing ...
(Date:1/19/2017)... 18, 2017 The global biotechnology services ... billion by 2025, according to a new report ... been adaptive of the function of outsourcing certain ... Among the services outsourced, clinical trial management and ... & Johnson was the first pharmaceutical company to ...
Breaking Biology Technology: